BNET Industries
- Private
- US
Dow Jones Description
Invitrogen is committed to being the leading provider of novel fluorescent reagents and detection solutions that advance scientific and biomedical research worldwide. Supplying superior Molecular Probes products and services, together with striving for customer and employee satisfaction, will be the driving forces of our organization.
Senior Vice President
Ben BulkleyNumber of Employees 0
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
invitrogen corp. and robotics and stock - All News and Analysis
Holiday season spurs strong November for stock indexes
Crude oil prices continue to play a significant role in driving stock market fluctuations. November saw oil prices fall from their record high of $55.67 per barrel last month to as low as $46.87 per barrel on November 15. Oil prices shot back up to over $50 per barrel due...
Roller coaster month ends on positive note for IBO indexes
A barrage of negative macroeconomic events early in October sent all three major US Stock Indexes tumbling, with the Dow Jones Industrial Average reaching an intraday low for the year at 9,708.40. The Labor Department's figures for September job growth came in much weaker than expected, with only 96,000 jobs...
Laboratory Instrument companies outpace US Indexes
Cautious optimism remains the theme for the US economy in general and for the three major US stock indexes as the summer comes to an end. During September, the Federal Reserve raised interest rates another quarter point to 1.75% as expected, noting that the economy is regaining some momentum after...
Economic concerns slow growth of IBO indexes in August
August proved to be a stagnant period for all major US stock indexes, with concerns over oil prices and terror threats. Investors were cautious at the beginning of the month when the Department of Homeland Security issued a warning about possible terror attacks on key US financial institutions. Stocks continued...
Instrument stocks' performances mixed in June
The final month of the first half of 2003 proved to be mediocre at best for the three major US stock indices, which all experienced minimal growth between 1% and 2%. Consumer spending remained somewhat sluggish, leaving the overall economy at a standstill. On the 26th of June, the Federal...
Three IBO stock indices post losses for January
For the most part, the economic news in January was fairly positive. The government reported that in the last three months of 2001, the economy grew at a rate of 0.2% as compared to the third quarter decline of 1.3%. After the end of the first month of 2002,...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Ben Bulkley | Senior Vice President |
| David U'Prichard | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Donald W Grimm | Board Member |
| Raymond V. Dittamore | Board of Directors |
| W. Ann Reynolds PhD | Board of Directors |
| Ronald W Lennox | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Invitrogen Corporation | Senior Vice President | Current |
| UCSD-CONNECT | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Care Capital, LLC | Venture Partner | Current |
| Red Abbey, LLC | Senior Advisor and Venture Partner | Current |
| University of Glasgow | Honorary Professor | Current |
| Red Abbey, LLC | Advisor | Current |
| Northwestern University | Associate Professor | Current |
| Glasgow University | Honorary Professor | Current |
| Genematrix, Inc. | Board Director | Current |
| Exsar Corporation | Board Director | Current |
| Guilford Pharmaceuticals, Inc. | Director | Current |
| Invitrogen Corporation | Director | Current |
| Cyclacel Limited | Board of Directors | Current |
| GlaxoSmithKline Plc | President | Former |
| SmithKline Beecham Corporation | President of Research and Development | Former |
| Druid Consulting | President | Former |
| Apax Partners Ltd. | Venture Partner | Former |
| Northwestern University School of Medicine | Associate Professor of Pharmacology and Neurobiology | Former |
| Biotechnology Industry Organization | member | Former |
| GlaxoSmithKline Plc | Chairman of Research and Development | Former |
| SmithKline Beecham Corporation | Chairman of R&D | Former |
| Biotechnology Industry Organization | Board Member | Former |
| University of Kansas | Ph.D. in Pharmacology | Former |
| University of Kansas | MS | Former |
| University of Glasgow | B.Sc. in Pharmacology | Former |
| Organization | Position | Status |
|---|---|---|
| Industry Ventures | Founder, Chairman and President, Strategic Design | Current |
| Biolayer Corporation Limited | Founder, Chairman and President, Strategic Design | Current |
| Microseq | Founder, Chairman and President, Strategic Design | Current |
| Seqanswers | Founder, Chairman and President, Strategic Design | Current |
| IDEXX Laboratories, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Strategic Design | President | Current |
| Molecular Probes | Founder, Chairman and President, Strategic Design | Current |
| Bioreliance Corporation | Founder, Chairman and President | Current |
| Emiliem, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Ionsource, LLC | Founder, Chairman and President, Strategic Design | Current |
| Olink | Founder, Chairman and President, Strategic Design | Current |
| Resgen Inc. | Founder, Chairman and President, Strategic Design | Current |
| Oligoperfect | Founder, Chairman and President, Strategic Design | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Founder, Chairman and President, Strategic Design | Current |
| Biocare Medical, LLC. | Founder, Chairman and President | Current |
| Hamilton BioVentures | President | Current |
| Aegis Therapeutics, LLC | Executive Chairman | Current |
| Strategic Design | Chairman | Current |
| San Diego Regional Chamber of Commerce | Vice Chair | Current |
| Cellzdirect, Inc. | Board of Directors | Current |
| Invitrogen Corporation | Board Member | Current |
| Hamilton BioVentures | Director | Current |
| Intec Telecommunications | Board Member | Current |
| Scripps Clinic | Board Member | Current |
| Multiple Peptide Systems Inc | Board of Directors | Current |
| Angstrom Pharmaceuticals, Inc. | Board of Directors | Current |
| High Throughput Genomics, Inc. | Board of Directors | Current |
| Dura Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| Hybritech, Inc. | CEO | Former |
| Biosource International, Inc. | Founder, Chairman and President, Strategic Design | Former |
| Hybritech, Inc. | President | Former |
| Copenhagen Capacity | Managing Director | Former |
| Eli Lilly and Company | Director of Pharmaceutical Market Research | Former |
| Hybritech, Inc. | Director of West Coast Pharmaceutical Sales | Former |
| Eli Lilly and Company | management positions | Former |
| U.S. Army | Officer | Former |
| Cadence Pharmaceuticals, Inc. | Former | |
| Biovail Corporation | Chairman | Former |
| Hybritech, Inc. | Chairman | Former |
| Hybritech | Chairman | Former |
| Roundtable Inc. | Board of Directors | Former |
| California Healthcare Institute, Inc. | Board of Directors | Former |
| Pharmaceutical Market Research | Director | Former |
| Somaxon Pharmaceuticals, Inc. | Board of Directors | Former |
| Bioreliance Corporation | Director | Former |
| Baldwin-Wallace College | Master's Degree In Business Administration | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | M.B.A. | Former |
| University of Pittsburgh | M.B.A. | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | B.S. In Pharmacy | Former |
| University of Pittsburgh | B.S. In Pharmacy | Former |
Raymond V. Dittamore has served as a Director of the Company since December 2002. Mr. Dittamore is a retired audit partner of Ernst & Young LLP, an international accounting firm. Mr. Dittamore retired in 2001 after 35 years of service with that firm, including 14 years as the managing partner of the firms San Diego office. Mr. Dittamore is also a director of Invitrogen Corporation, Gen-Probe Incorporated, and Digirad Corporation. Mr. Dittamore received a B.S. degree from San Diego State University.
| Organization | Position | Status |
|---|---|---|
| QUALCOMM Incorporated | Board of Directors | Current |
| Molecular Probes | Director | Current |
| Invitrogen Corporation | Board of Directors | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Biolayer Corporation Limited | Director | Current |
| Ionsource, LLC | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Gen-Probe Inc. | Board of Directors | Current |
| Applied Molecular Evolution, Inc. | Director | Current |
| Ernst & Young | partner | Former |
| Ernst & Young | collaborative editor | Former |
| Digirad Corporation | Board of Directors | Former |
| San Diego State University | B.S. | Former |
| QUALCOMM Incorporated | member | Former |
Director since February 2005. Dr. Reynolds is the former President of the University of Alabama at Birmingham. She retired as Director, Center for Community Outreach and Development, The University of Alabama at Birmingham in 2003. Prior to joining The University of Alabama at Birmingham as President in 1997, Dr. Reynolds served as Chancellor of the City University of New York, where she was responsible for the 21 colleges and professional schools that comprised that system. Prior to that, Dr. Reynolds was the Chancellor of the California State University system, chief academic officer of Ohio State University and associate vice chancellor for research and dean of the graduate college of the University of Illinois Medical Center. Earlier in her career, she held appointments as professor of anatomy, research professor of obstetrics and gynecology, and acting associate dean for academic affairs at the University of Illinois College of Medicine. A native of Kansas, Dr. Reynolds holds a M.S. and a Ph.D. in zoology from the University of Iowa, as well as a B.S. in biology from Emporia State University, Kansas. She was a National Science Foundation Predoctoral Fellow and an honorary Woodrow Wilson Fellow. Dr. Reynolds is a director of Abbott Laboratories, Humana Inc., Owens Corning and the Champaign-Urbana News Gazette.
| Organization | Position | Status |
|---|---|---|
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Emiliem, Inc. | Board of Directors | Current |
| CHANGENOW4HEALTH | Member of The Board of The Champaign, Urbana News Gazette In Illinois | Current |
| Humana Inc. | Board of Directors | Current |
| Abbott Laboratories | Board of Directors | Current |
| News Gazette Inc. | Director | Current |
| Olink | Board of Directors | Current |
| Biocare Medical, LLC. | Board of Directors | Current |
| Owens Corning | Board of Directors | Current |
| Business-Higher Education Forum | Member of The Board of The Champaign, Urbana News Gazette | Current |
| Industry Ventures | Board of Directors | Current |
| Abms Member | Board of Directors | Current |
| Invitrogen Corporation | Board of Directors | Current |
| KMG America Corporation | Member of The Board of The Champaign, Urbana News Gazette | Current |
| Resgen Inc. | Board of Directors | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Maytag Corporation | Board of Directors | Current |
| Ionsource, LLC | Board of Directors | Current |
| The University of Alabama at Birmingham | President | Former |
| University of Illinois | Professor | Former |
| University of Illinois College of Medicine | Research Professor | Former |
| Emporia State University | M.S. | Former |
| Emporia State University | Bachelors Degree In Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Geneohm Sciences, Inc. | Partner At Collinson Howe & Lennox, LLC. | Current |
| CHL Medical Partners, L.P. | Partner | Current |
| Opgen, Inc. | Chairman of The Board of Opgen and Partner | Current |
| Youngstartup Ventures, Inc. | Partner, Chl Medical Partners | Current |
| Biorelix, Inc. | Board of Directors | Current |
| American Renal Associates Inc | Director | Current |
| Tyco International Ltd. | Board of Directors | Current |
| Becton, Dickinson & Company | Board of Directors | Current |
| Geneohm Sciences, Inc. | Board of Directors | Current |
| Primera Biosystems, Inc | Board of Directors | Current |
| Invitrogen Corporation | Board of Directors | Current |
| CGI Pharmaceuticals, Inc. | CEO | Former |
| HarbourVest Partners, LLC | Partner | Former |
| CHL Medical Partners, L.P. | Team Member | Former |
| Amicus Therapeutics, Inc. | Chairman | Former |
| Cellular Genomics | Chairman | Former |
| Fox Chase Cancer Center | Board Member | Former |
| The Johns Hopkins University | Board Member | Former |
| Point Biomedical Corporation | Board of Directors | Former |
| University of Glasgow | B.Sc. In Molecular Biology | Former |
| University of Glasgow | Degree In Molecular Biology | Former |
| University of Oxford | DPhil in Cell Biology | Former |
| Wharton Graduate School of the University of Pennsylvania | graduate | Former |
| The Wharton School of the University of Pennsylvania | Former |
Industry Transcripts by Seeking Alpha
-
Schiff Nutrition International, Inc. F3Q10 (Qtr End 02/28/10) Earnings Call Transcript
on Mar 17, 2010about WNI
-
XOMA Ltd. Q4 2009 Earnings Call Transcript
on Mar 11, 2010about XOMA
-
Peregrine Pharmaceuticals, Inc. F3Q10 (Qtr End 01/31/10) Earnings Call Transcript
on Mar 11, 2010about PPHM
-
Mannatech, Incorporated Q4 2009 Earnings Call Transcript
on Mar 11, 2010about MTEX
-
Chelsea Therapeutics International, Ltd. Q4 2009 Earnings Call Transcript
on Mar 10, 2010about CHTP
IndustryTop Rated
- The 5 Worst Drug Companies of 2009 3 votes
- If Approved -- FDA Drug Labeling Could Decide Ultimate Success of MannKind's Afrezza 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- Efficacy of Roche's Flu Drug Tamiflu In Doubt 3 votes
- 2010 FDA Approvals Could Lead to Launch of Eight Blockbuster Biotech Drugs 3 votes


